A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, *endoglin* and *ALK-1*

G M F Wallace, C L Shovlin

Abstract

Background—Pulmonary arteriovenous malformations (PAVMs) occur in over 25% of patients with the autosomal dominant disorder hereditary haemorrhagic telangiectasia (HHT). Mutations in two genes, *endoglin* and *ALK-1*, are known to cause HHT. Each encodes a protein expressed on vascular endothelial cells and involved in signalling by members of the transforming growth factor (TGF)- β superfamily. To date, PAVMs have not been detected in *ALK-1* families. There is evidence from a single HHT family without pulmonary involvement that a third HHT gene may exist. To establish the existence of a further HHT gene responsible for PAVMs, linkage analyses were performed on an expanded PAVM-HHT family in which HHT did not result from *endoglin* mutations.

Methods—Family members were assessed clinically to assign HHT disease status and were screened for PAVMs. DNA was extracted from blood obtained from 20 individuals of known disease status. Short tandem repeat polymorphic markers spanning the intervals containing the *endoglin* and *ALK-1* genes were amplified by the polymerase chain reaction using ³³P-labelled oligonucleotide primers, separated by denaturing polyacrylamide gel electrophoresis (PAGE), and the resultant autoradiographs were examined for allele sizes. Linkage analyses were performed using MLINK and GENE-HUNTER.

Results—Twelve members spanning four generations were affected with HHT. Two had proven PAVMs, one with a classical appearance, the other exhibiting microscopic PAVMs exacerbated by pregnancy. Two point lod and multipoint lod scores significantly excluded linkage to *endoglin* and *ALK-1* in this pedigree.

Conclusions—This study confirms the existence of a third HHT locus that accounts for disease in some HHT patients with pulmonary involvement.

(Thorax 2000;55:685-690)

Keywords: genetic linkage; pulmonary arteriovenous malformations; transforming growth factor β

Figure 1 Pedigree of family S. Affected individuals are indicated by black symbols, unaffected by white symbols. Squares represent males, circles represent females, and a slashed symbol indicates a deceased individual. Individuals of unknown status are not illustrated.

either through complex vascular structures supplying and draining a bulbous aneurysmal sac¹ or through smaller calibre telangiectatic vessels. The full picture of complications is still emerging.² Most can be attributed to the right-to-left (R-L) shunt that may exceed 40% of the cardiac output in severe cases. Hypoxaemia is common but is usually well tolerated by the patient because of the attendant low pulmonary vascular resistance. However, cerebral abscesses, cerebrovascular accidents, and transient ischaemic attacks due to paradoxical embolism through the PAVMs result in considerable morbidity and mortality.³⁻⁶ Although individual PAVMs are amenable to surgical resection, in most individuals multiple lesions are likely with time and therefore the advent of the parenchymal-sparing embolisation techniques has transformed the outlook for patients.⁷ To reduce the incidence of paradoxical embolism, embolisation of all feasible PAVMs is recommended with antibiotic prophylaxis for dental and surgical procedures in all patients with residual shunts.^{2,8} As up to 50% of patients with PAVMs are asymptomatic before a cerebral event, this highlights the need for effective clinical screening methods for PAVMs.

More than 70% of PAVMs occur in patients with hereditary haemorrhagic telangiectasia (HHT, Rendu-Osler-Weber syndrome), a vascular disorder inherited as an autosomal dominant trait. HHT has a prevalence rate of about one in 10 000 in Europe⁹ and classically presents with epistaxis and telangiectasia, particularly on the lips, tongue, buccal mucosa, and digits.^{10,11} Gastrointestinal bleeding due to telangiectasia occurs in approximately one third of patients, especially in later life, and is well recognised. However, the significance of AVMs in the pulmonary (>25%), hepatic (8-16%), and cerebral (15%) circulations is often overlooked. Although all three can cause

Rayne Laboratories,
Respiratory Medicine,
University of
Edinburgh,
Edinburgh, UK
G M F Wallace

Respiratory Medicine,
Imperial College
School of Medicine,
National Heart and
Lung Institute,
Hammersmith
Hospital, London
W12 0NN, UK
C L Shovlin

Correspondence to:
Dr C L Shovlin
email: c.shovlin@ic.ac.uk

Received 6 December 1999
Returned to authors
21 February 2000
Revised version received
18 April 2000
Accepted for publication
18 April 2000

Pulmonary arteriovenous malformations (PAVMs) provide a direct communication between the pulmonary arterial and venous systems without an intervening capillary bed,

Table 1 Clinical features of family members

Individual	Age* (years)	Epistaxis			PAVM screen		HHT status
		Onset	Current severity	Telangiectasia	SaO ₂ supine	SaO ₂ erect	
II.2	69	Childhood	Occasional	Buccal	98	97	Affected
II.3	76	—	—	—	97	97	Unaffected
III.1	49	Childhood	Nil since childhood	Lips, facial	96	96	Affected
III.2	48	Childhood	Nil since cauterisation	—	98	97	Obligate affected
III.4	48	Childhood	2 monthly	Facial	100	100	Affected
III.6	42	Childhood	Frequent, several cauterisations	Lips, buccal	98	98	Affected
IV.2	28	Preschool	Almost daily	Buccal, tongue, fingers	96	95	Affected
IV.3	27	26 years	Monthly	Lips, hands	98	94	Affected
IV.4	19	Childhood	Occasional	Lips, facial	99	98	Affected
IV.5	17	Childhood	Weekly	Buccal	99	98	Affected
IV.6	9	Aged four	Several per year	Tongue	98	98	Affected
IV.7	18	Childhood	Occasional	Buccal	98	98	Affected
IV.8	16	—	—	—	98	98	Unaffected
V.1	9	Preschool	Several each year	Facial, fingers	98	97	Affected

SaO₂ = oxygen saturation on air after 10 minutes in posture indicated.

*Age (years) at time of review.

Pedigree numbers correspond to fig 1. See text for additional clinical information on IV.2 and IV.3.

considerable mortality and morbidity, only PAVM treatment can be safely attempted in all patients. Thus, PAVM screening programmes have been targeted towards patients with HHT,^{12,13} with attempts made to identify genetic subgroups of HHT patients who are at particular risk of developing PAVMs.

Linkage studies assigned the first HHT disease locus to chromosome 9^{14,15} and the disease gene was subsequently identified as *endoglin*.¹⁶ The second HHT locus, *HHT2*, was mapped to chromosome 12^{17,18} and the mutated gene identified as *ALK-1*.¹⁹ Linkage studies on one HHT family with an unusual predominance of hepatic AVMs (and no pulmonary involvement) indicated that this pedigree was not linked to *endoglin* or *ALK-1*, suggesting the likelihood of a third HHT gene,²⁰ although the exact locus and mutated gene have yet to be identified. *Endoglin* and *ALK-1* encode transmembrane proteins expressed predominantly on vascular endothelial cells and implicated in signalling by members of the transforming growth factor (TGF)- β superfamily.^{21,22} Numerous mutations have been described in *endoglin*^{16,23–29} and *ALK-1*,^{19,30,31} although no phenotypic differences have been ascribed to particular mutations within these genes. There appear to be differences between *endoglin* and non-*endoglin* families: PAVMs have been seen predominantly in *endoglin*-linked families³² and, to date, no *ALK-1* linkage or mutations have been described in patients with PAVMs (although only a small number have been screened). These data have led some to suggest that clinical screening for PAVMs should be restricted to *endoglin*-linked families.¹⁰

In this paper we extend previous findings indicating that a PAVM-HHT family is unlinked to *endoglin* and now show that, in this pedigree, HHT is also unlinked to *ALK-1*. This confirms an earlier report that there is at least one further HHT locus, and extends this observation to HHT patients with PAVMs. A PAVM-HHT family linked to *ALK-1* is also described briefly. We discuss the implications for clinical practice and our understanding of the biology of the TGF- β signalling pathways and pathophysiology of HHT.

Figure 2 PAVM patient data. (A) Post embolisation chest radiograph of case IV.2 indicating the presence of PAVM embolisation coils. (B) Perfusion scan using ^{99m}Tc-labelled albumin macroaggregates on case IV.3. The significant cerebral activity indicates the presence of a right-to-left shunt quantified as 7.2% of the cardiac output (normal in this institution <3.5%).¹² In view of the recent suggestion that contrast echocardiography may be used in isolation as a first line screen for PAVMs in patients with HHT¹³ it is worth noting that, in this patient, previously positive contrast echocardiography was negative on the day of the perfusion scan, a discrepancy which may be attributable to altered posture before and during the relevant examinations.

Methods

CLINICAL EVALUATIONS

These studies were performed with the approval of the Multicentre Research Ethics Committee of Scotland (MREC 98/0/42). With informed consent, both authors assessed additional and original members of families previously identified and screened by CLS.^{14 24} Clinical evaluation included full history, physical examination for telangiectasia, cyanosis, and finger clubbing, oximetry measured by an Ohmeda 3800 oximeter for 10 minutes in both erect and supine postures and, when appropriate, full blood counts. Additional information was obtained from local physicians.

Disease status was designated using the current international consensus criteria.³³ Affected status was assigned in the presence of any three of the following criteria: affected first degree relative; recurrent spontaneous epistaxis; mucocutaneous telangiectasia; and documented visceral manifestations. If only two of the four criteria were present (affected first degree relative and epistaxis), unknown status was assigned and the individual excluded from molecular analyses. However, if both a parent and child of the individual were affected, a diagnosis of obligate affected was made.

ASCERTAINMENT OF GENOTYPE

All affected and unaffected family members were venesected to provide blood for genetic analyses. DNA was extracted from whole blood using proteinase K digestion, phenol- chloroform extraction, and ethanol precipitation, with resuspension in Tris-buffered EDTA.³⁴ Linkage studies were performed by analysis of short tandem repeat (STR) polymorphic markers as previously described.¹⁴ Markers of high heterozygosity were chosen on the basis of their position relative to the genes of interest and experience in previous molecular papers

(*endoglin*,^{14 16} *ALK-1*^{17 19}). Primer sequences are published elsewhere.^{35 36} The STRs were amplified by the polymerase chain reaction (PCR) using approximately 25 ng DNA template, 20 ng of each PCR primer (forward primer labelled with ³³P) in 10 µl reactions with *Taq* DNA polymerase as previously described.¹⁴ Reaction times in a PTC-100 thermal cycler (MJ Research) were typically 30 cycles of 95 degrees for 20 seconds, primer specific amplification temperature for 40 seconds, and 72 degrees for 60–100 seconds according to product length. The products were size separated by denaturing polyacrylamide gel electrophoresis and detected by autoradiography. Allele patterns were assessed by eye by two observers blinded to disease status.

LINKAGE ANALYSES

Two point and multipoint analyses were performed using MLINK and GENEHUNTER³⁷ via Human Genome Mapping Project (HGMP) computational resources. Based on previously published estimates⁹ and our previous studies in this population,¹⁴ penetrance was set at P = 0.8 for individuals aged 12–35 and P = 0.95 for those aged over 35, giving two liability classes. Apparently unaffected children under the age of 12 years were excluded as penetrance is less than 80% at this age.¹⁴ A disease gene frequency of 0.0001 was used and recombination rates were assumed to be equal in both sexes. Lod scores were calculated initially with equal allele frequencies, and subsequently according to the allele frequencies in the population.

The linkage analyses were targeted at the three HHT-PAVM families which we previously reported as unlinked to *HHT1/endoglin*, with no mutations in the coding regions of *endoglin*.²⁴ The first, family T,¹⁴ was insufficiently informative to obtain significantly negative lod scores across the entire *ALK-1* interval. The second, family V, in which one of six affected members had PAVMs presenting with clubbing and a 25% R-L shunt, was linked to *ALK-1* (Z = 1.48, θ = 0.00, *D12S368*), although the exact mutation has not yet been identified. In this paper we present data on the third of these pedigrees.

Table 2 Pairwise lod scores between chromosome 9 loci and HHT

Locus	Recombination fraction (θ)							
	0	0.01	0.05	0.1	0.2	0.3	0.4	0.5
D9S60	-16.67	-8.99	-5.38	-3.52	-1.72	-0.79	-0.26	0
D9S315	-16.07	-7.67	-4.93	-3.21	-1.57	-0.72	-0.25	0
D9S61	-10.33	-5.58	-2.88	-1.74	-0.74	-0.31	-0.11	0

Lod scores were calculated at different recombination fractions (see Methods).

A

B

Figure 3 Exclusion of *endoglin* as the disease gene. (A) Position of *endoglin* gene relative to flanking markers in the 2 cM interval between D9S60 and D9S61. Relevant physical distances (in Mb) are indicated below the horizontal line. The relative positions of *endoglin* and AK1 have not been resolved. (B) Multipoint lod scores across the HHT1 (*endoglin*) interval calculated using LINKMAP (similar figures were obtained between D9S60 and D9S61 using GENEHUNTER, data not shown).

Results

CLINICAL RESULTS

The expanded pedigree of family S, previously briefly described by Shovlin *et al.*²⁴ is illustrated in fig 1. The results of the clinical investigations are summarised in table 1. Twelve members spanning four generations were affected by HHT as defined by positive family history, epistaxes, and telangiectasia. Individual III.2 was classified as an obligate affected as she had an affected parent and two affected children, although personally fulfilled only two diagnostic criteria. Three further individuals who were offspring of affected family members had epistaxis alone and no affected children; they were therefore classified as being of unknown status and are not illustrated here, nor are the five offspring of affected family members who were unavailable for review.

Two members of the family had PAVMs. The proband IV.2 presented with haemoptysis, clubbing, polycythaemia (Hb 18.9, haematocrit 0.55), hypoxaemia (PaO₂ 8.2 kPa), and orthodeoxia (supine SaO₂ 92%, erect 87%). The R-L shunt measured by ^{99m}technetium-labelled albumin macroaggregates (radionucleotide scanning) was 24% of the cardiac output (normal range in this institution <3.5%).¹² Two large PAVMs were successfully embolised with steel coils (fig 2A). Although individual IV.3 was asymptomatic with normal oxygen saturations (SaO₂ 100% in supine and erect postures) when first evaluated at the age of 21 years, following pregnancy at the age of 26 she developed monthly epistaxes, frequent dizzy spells, and significant orthodeoxia (SaO₂ 99% supine, 94% erect). Microscopic PAVMs were diagnosed on the basis of a positive contrast

echocardiogram (15 months post partum), a R-L shunt of 7.2% six months later (fig 2B), and a normal thoracic axial computed tomographic (CT) scan at 5 mm intervals. She remains on prophylactic antibiotic therapy and under regular respiratory review.

EXCLUSION OF ENDOGLIN

Linkage studies were first performed to confirm exclusion of linkage to *endoglin*, as previously reported in a subsection of the pedigree.²⁴ The *HHT1* locus was originally mapped to a 2 cM interval on chromosome 9 flanked by *D9S60* and *D9S61*.¹⁴ (The adjacent *D9S61*-*D9S63* interval described by McDonald *et al.*¹⁵ was subsequently revised by McAllister *et al.*¹⁶ to between *D9S60* and *D9S61*.) The *endoglin* gene has been mapped physically as equidistant between *D9S315* and the non-erythrocytic α -spectrin gene *SPTAN*, which both lie within the interval flanked by *D9S60* and *D9S61* (fig 3A, unpublished data).²⁴ Markers *D9S60*, *D9S315*, and *D9S61* were used for linkage studies as they are more polymorphic than STRs associated with *endoglin* and *SPTAN*.²⁴

Two point lod score calculations using age related penetrance indicated that HHT was not linked to markers in this interval (table 2). Lod scores were not significantly different when calculated using altered allele frequencies (results not shown). Multipoint linkage calculations using the three loci also indicated that the HHT gene does not map to the interval, and excludes *endoglin* as the disease gene in this family (fig 3B).

EXCLUSION OF ALK-1

We then performed analyses to assess linkage to *ALK-1*. Two original assignments of the *HHT2* locus were given, one between *D12S339* and *D12S359*¹⁷ and the other in a neighbouring interval between *D12S345* and *D12S339*¹⁸ (fig 4A). The latter was revised on subsequent analyses, and the *ALK-1* gene is now known to lie in the 4 cM interval between *D12S347* and *D12S359*, most probably in the 1 cM interval between *D12S347* and *D12S368*.¹⁹

Table 3 Pairwise lod scores between chromosome 12 loci and HHT

Locus	Recombination fraction (θ)							
	0	0.01	0.05	0.1	0.2	0.3	0.4	0.5
D12S331	-4.81	-4.76	-3.39	-2.26	-1.17	-0.59	-0.23	0
D12S85	-4.67	-4.64	-4.57	-4.19	-2.39	-1.25	-0.50	0
D12S347	-9.07	-5.14	-4.60	-3.89	-2.16	-1.14	-0.47	0
D12S368	-5.27	-1.67	-0.97	-0.68	-0.39	-0.22	-0.10	0
D12S325	-8.78	-4.84	-4.34	-4.00	-2.38	-1.29	-0.55	0

Figure 4 Exclusion of *ALK-1* as the disease gene. (A) Position of *ALK-1* gene relative to flanking markers. All distances are indicated in cM according to Gyapár *et al.*³⁵ The probable *ALK-1* site is indicated by a double bar, with possible extension indicated by a single bar.¹⁹ The dotted line indicates one of the original intervals¹⁸ which has now been revised.¹⁹ (B) Multipoint lod scores across the HHT2 (*ALK-1*) interval calculated using LINKMAP (similar figures were obtained between *D12S331* and *D12S325* using GENEHUNTER, data not shown).

Figure 5 Limited haplotype analyses. Haplotypes in a section of the pedigree including the two PAVM patients. (A) Chromosome 9 markers spanning endoglin. In affected individuals IV.2, IV.3, and V.1 all haplotypes (B, C and D) are derived from unaffected spouses. (B) Chromosome 12 markers spanning ALK-1. In affected individuals IV.2 and V.1 all haplotypes (B, C and D) are derived from unaffected spouses. Note the recombination event which has occurred in IV.3.

Nevertheless, we considered it prudent to examine both disease intervals.

Two point lod score calculations using age related penetrance indicated that HHT was not linked to markers spanning the entire region (table 3). Lod scores were not significantly different when calculated using altered allele frequencies (results not shown). Multipoint linkage calculations using four loci spanning the disease interval also indicated that the HHT gene does not map to the region, and excludes *ALK-1* as the disease gene in this family (fig 4B).

Limited haplotype analyses on the subsection of the pedigree involving the PAVM patients provided further confirmation of exclusion of both known HHT genes (fig 5).

Discussion

We have shown by two point and multipoint linkage analyses that a large HHT pedigree with proven pulmonary involvement is significantly unlinked to the two known HHT genes, *endoglin* and *ALK-1*. This confirms an earlier report that there is at least one further HHT locus²⁰ and extends this observation to HHT patients with PAVMs.

Since incorrect assignment of the HHT phenotype could result in false negative lod scores, it is important to re-examine the phenotypes in all members of family S (table 1). All phenotypes were assigned before the molecular studies and only DNA from unequivocally affected or unaffected individuals was ana-

lysed. On both chromosome 9 and chromosome 12, of the four affected individuals in generation III (three of whom were parents or grandparents of affected individuals), two displayed one haplotype which could be traced to their affected parent II.2, and two the alternative. Analyses of the haplotypes transmitted to and by the PAVM patients were particularly instructive (fig 5) and further confirmed that HHT in this family cannot result from mutations in either *endoglin* or *ALK-1*.

Could this have been suspected before the molecular studies? There is a wide variation in disease expression between individuals with HHT. Most patients experience nose bleeds of varying severity and display mucocutaneous telangiectasia which increase with age, but the disease spectrum ranges from non-penetrance in 3% of carefully examined patients⁹ to significant involvement of visceral vascular beds. As in most HHT families, the affected individuals in this pedigree span all categories. We cannot comment on the incidence of cerebral or hepatic manifestations in this family as asymptomatic screening for these complications is not performed routinely in the United Kingdom. However, before this study, based on the behaviour and incidence of the PAVMs in two of 12 affected individuals, the literature on HHT might have suggested family S to be an *endoglin* family. The clinical presentation and embolisation response of family member IV.2 reflect most patients with PAVMs who present symptomatically. Family member IV.3 represents one of the more recently recognised cases of microscopic PAVMs detected essentially by a screening programme. The apparent precipitation of her symptoms and PAVMs by pregnancy is well recognised.³⁸ Although there is only one report illustrating a partial spontaneous improvement post partum,³⁹ we believe this pattern is likely to reflect the physiological behaviour of PAVMs rather than her underlying HHT genotype.

The pulmonary involvement present in members of non-*endoglin* families has significant implications for clinical PAVM screening which is critical since patients are often asymptomatic at the time of cerebrovascular events and, particularly, cerebral abscesses.² Available data still suggest that the detection rate for PAVMs will be higher in the *endoglin*-linked families. However, our data support the view that PAVM screening should be performed in all HHT patients as PAVMs may be present in individuals from families linked to *ALK-1* (family V) or families unlinked to either known locus (current data). The development of PAVMs in individual IV.3, who is one of the few reported cases in whom serial screening has been undertaken, highlights the importance of rescreening, particularly after pregnancy.

As well as the clinical implications, this family should provide an additional means of dissecting the complexities of signalling by the TGF- β superfamily by the ultimate identification of the mutated gene. *Endoglin* and *ALK-1* are both involved in the regulation of the response to ligands of the TGF- β superfamily, but the natural ligands and important functional signalling complexes for each have yet to

be determined. Endoglin is an accessory protein for several receptor complexes of the TGF- β superfamily; in addition to its relatively well recognised involvement in signalling by TGF- β 1 and TGF- β 3, recent data suggest that endoglin might also be involved in signalling by bone morphogenetic proteins (BMPs) or activins.²² Similarly, while ALK-1 is currently an orphan type I TGF- β receptor with no assigned natural ligand, there is evidence that it too may bind TGF- β ligands from several different subfamilies.⁴⁰ It seems reasonable to speculate that the gene mutated in the pedigree described here may encode another component of the TGF- β signalling complex or downstream effectors, and its identification should significantly enhance our understanding of signalling by TGF- β family members. Many of these are implicated in vascular development, homeostasis, and repair (references cited by Shovlin *et al*²² and Pece-Barbara²²).

However, we should note that, for endoglin, identification of the HHT mutations, insights into biochemical functions relevant to the vasculature,⁴¹ and now the availability of murine models of HHT⁴²⁻⁴³ have yet to translate into a clear understanding of the pathophysiology of HHT. Thus, even following the identification of the gene(s) responsible for HHT in this and the pedigree previously described,²⁰ there may remain a significant gap between our knowledge of the molecular abnormalities of HHT and the means by which these precipitate the development of abnormal vascular structures and, particularly, PAVMs.

GMFW is a British Heart Foundation Junior Fellow and CLS is supported by the Wellcome Trust. The authors would like to acknowledge the contributions of Dr H R Gribben, Dr D J M Sinclair, and Professor J M B Hughes to the clinical management of cases IV.2 and IV.3, and Dr J E Jackson who performed the angiography and embolisation of case IV.2. D Glass performed the radionuclide shunt measurements, Dr M Blomley and Dr P Nihoyannopoulos performed echocardiography assessments, and C I Mordin and J Curtis carried out pulmonary function testing. We would also like to thank the family members and their general practitioners for their cooperation in these studies.

- 1 White RI, Mitchell SE, Barth KH, *et al*. Angioarchitecture of pulmonary arteriovenous malformations: an important consideration before embolotherapy. *AJR* 1983;140:681-6.
- 2 Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. *Thorax* 1999;54:714-29.
- 3 Dines DE, Arms RA, Bernatz PE, *et al*. Pulmonary arteriovenous fistulas. *Mayo Clin Proc* 1974;49:460-5.
- 4 Sluiter-Eringa H, Orie NGM, Sluiter HJ. Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients. *Am Rev Respir Dis* 1969;100:177-88.
- 5 Stringer C, Stanley A, Bates R, *et al*. Pulmonary arteriovenous fistula. *Am J Surg* 1955;89:1054-80.
- 6 Yater W, Finnegan J, Giffin H. Pulmonary arteriovenous fistula (varix). *JAMA* 1949;141:581-9.
- 7 Hughes JMB, Allison DJ. Pulmonary arteriovenous malformations: the radiologist replaces the surgeon. *Clin Radiol* 1990;41:297-8.
- 8 Saluja S, Sitko I, Lee DW, *et al*. Embolotherapy of pulmonary arteriovenous malformations with detachable balloons: long term durability and efficacy. *J Vasc Intervent Radiol* 1999;10:883-9.
- 9 Plauchu H, de Chadarevian J-P, Bideau A, *et al*. Age-related profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. *Am J Med Genet* 1989;32:291-7.
- 10 Guttacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. *N Engl J Med* 1995;333:918-24.
- 11 Haitjema T, Westermann CJJ, Overtom TTC, *et al*. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): new insights in pathogenesis, complications, and treatment. *Arch Intern Med* 1996;156:714-9.
- 12 Thompson RD, Jackson JE, Peters AM, *et al*. Sensitivity and specificity of radioisotope right-left shunt measurements and pulse oximetry for the early detection of pulmonary arteriovenous malformations. *Chest* 1999;115:109-13.

- 13 Kjeldsen AD, Oxhøj H, Andersen PE, *et al*. Pulmonary arteriovenous malformations: Screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia. *Chest* 1999;116:432-9.
- 14 Shovlin CL, Hughes JMB, Tuddenham EGD, *et al*. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. *Nat Genet* 1994;6:205-9.
- 15 McDonald MT, Papenberg KA, Ghosh S, *et al*. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. *Nature Genet* 1994;6:197-204.
- 16 McAllister KA, Grogg KM, Johnson DW, *et al*. Endoglin, a TGF- β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. *Nature Genet* 1994;8:345-51.
- 17 Vincent P, Plauchu H, Hazan J, *et al*. A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q. *Hum Mol Genet* 1995;4:945-9.
- 18 Johnson DW, Berg JN, Gallione CJ, *et al*. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. *Genome Res* 1995;5:21-8.
- 19 Johnson DW, Berg JN, Baldwin MA, *et al*. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. *Nature Genet* 1996;13:189-95.
- 20 Piantanida M, Buscarini E, Dellavecchia C, *et al*. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. *J Med Genet* 1996;33:441-3.
- 21 Heldin C-H, Miyazono K, ten Dijke P. TGF- β signalling from cell membrane to nucleus through SMAD proteins. *Nature* 1997;390:465-71.
- 22 Pece BN, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor- β superfamily. *J Biol Chem* 1999;274:584-94.
- 23 McAllister KA, Baldwin MA, Thukkani AK, *et al*. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type I suggest a dominant-negative effect of receptor function. *Hum Mol Genet* 1995;4:1983-5.
- 24 Shovlin CL, Hughes JMB, Scott J, *et al*. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. *Am J Hum Genet* 1997;61:68-79.
- 25 Pece-Barbara N, Vera S, Cymerman U, *et al*. Mutant endoglin in hereditary hemorrhagic telangiectasia type I is transiently expressed intracellularly and is not a dominant negative. *J Clin Invest* 1997;100:2568-79.
- 26 Yamaguchi H, Azuma H, Shigeyiyo T, *et al*. A novel missense mutation in the endoglin gene in hereditary hemorrhagic telangiectasia. *Thromb Haemost* 1997;77:243-7.
- 27 Gallione C, Klaus D, Yeh E, *et al*. Mutation and expression analysis of the endoglin gene in hereditary haemorrhagic telangiectasia. *Hum Mutat* 1998;11:286-94.
- 28 Pece-Barbara N, Cymerman U, Vera S, *et al*. Expression analysis of four endoglin missense mutations suggests haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type I. *Hum Mol Genet* 1999;8:2171-81.
- 29 Cymerman U, Vera S, Pece-Barbara N, *et al*. Identification of hereditary hemorrhagic telangiectasia type I in newborns by protein expression and mutation analysis of endoglin. *Pediatr Res* 2000;47:24-35.
- 30 Berg JN, Gallione C, Stenzel T, *et al*. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary haemorrhagic telangiectasia. *Am J Hum Genet* 1997;61:60-7.
- 31 Klaus D, Gallione C, Anthony K, *et al*. Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary haemorrhagic telangiectasia. *Human Mutation, Mutations in Brief Online* 1998; #164.
- 32 Berg JN, Guttacher AE, Marchuk DA, *et al*. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? *J Med Genet* 1996;33:256-7.
- 33 Shovlin CL, Guttacher AE, Buscarini E, *et al*. Diagnostic criteria for hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). *Am J Med Genet* 2000;91:66-7.
- 34 Sambrook J, Fritsch EF, Maniatis T. *Molecular cloning. A laboratory manual*. 2nd edn. Cold Spring Harbor Laboratory Press, 1989.
- 35 Gyapari G, Morissette J, Vignal A, *et al*. The 1993-94 Génethon human genetic linkage map. *Nature Genet* 1994;7:246-339.
- 36 GenBank. National Center for Biotechnology Information. <http://www.ncbi.nlm.nih.gov/> 1999.
- 37 Ott J. *Analysis of human genetic linkage*. 2nd edn. Baltimore: The Johns Hopkins University Press, 1992.
- 38 Shovlin CL, Winstock AR, Peters AM, *et al*. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. *Q J Med* 1995;88:879-87.
- 39 Hughes JMB, Shovlin CL, Simonds AK. Pulmonary disease and cor pulmonale. In: Oakley C, ed. *Heart disease in pregnancy*. London: BMJ Publishing Group, 1997: 180-200.
- 40 Lux A, Attisano L, Marchuk D. Assignment of transforming growth factor β 1 and β 3 and a third new ligand to the type I receptor ALK-1. *J Biol Chem* 1999;274:9984-92.
- 41 Letamandia A, Lastres P, Botella L, *et al*. Role of endoglin in cellular responses to transforming growth factor- β . *J Biol Chem* 1998;273:33011-9.
- 42 Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. *J Clin Invest* 1999; 104:1343-51.
- 43 Shovlin C. Supermodels and disease: insights from the HHT mice. *J Clin Invest* 1999;104:1335-6.